Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) CFO Richard Buchholz sold 15,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $230.03, for a total value of $3,450,450.00. Following the sale, the chief financial officer now directly owns 28,271 shares in the company, valued at approximately $6,503,178.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Inspire Medical Systems Stock Down 1.0 %
Shares of NYSE INSP traded down $2.39 during trading hours on Thursday, reaching $241.12. 880,106 shares of the stock traded hands, compared to its average volume of 536,585. The company’s 50-day simple moving average is $202.06 and its two-hundred day simple moving average is $183.36. The company has a market capitalization of $7.31 billion, a P/E ratio of -329.05 and a beta of 1.37. Inspire Medical Systems, Inc. has a 52-week low of $123.27 and a 52-week high of $330.00.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.53. The business had revenue of $192.51 million for the quarter, compared to analysts’ expectations of $186.75 million. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The business’s quarterly revenue was up 39.6% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share. As a group, sell-side analysts forecast that Inspire Medical Systems, Inc. will post -0.35 earnings per share for the current fiscal year.
Institutional Trading of Inspire Medical Systems
Analysts Set New Price Targets
Several research analysts recently weighed in on INSP shares. KeyCorp assumed coverage on shares of Inspire Medical Systems in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $278.00 price objective for the company. Morgan Stanley assumed coverage on Inspire Medical Systems in a research note on Tuesday, March 19th. They issued an “overweight” rating and a $250.00 target price on the stock. Jefferies Financial Group started coverage on Inspire Medical Systems in a research note on Friday, January 19th. They set a “buy” rating and a $245.00 price target for the company. Stifel Nicolaus reaffirmed a “hold” rating and set a $210.00 price objective on shares of Inspire Medical Systems in a report on Tuesday, January 2nd. Finally, Truist Financial reiterated a “buy” rating and issued a $280.00 target price on shares of Inspire Medical Systems in a research note on Wednesday, March 20th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $271.29.
Check Out Our Latest Analysis on INSP
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Read More
- Five stocks we like better than Inspire Medical Systems
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Comprehensive PepsiCo Stock Analysis
- Where Do I Find 52-Week Highs and Lows?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What are earnings reports?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.